May 2018 Vol 9, No 5
The Biden Cancer Initiative builds on former Vice President Joe Biden’s work on the National Cancer Moonshot Initiative by developing and driving implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research, and care, and to reduce disparities in cancer outcomes.
Efficacy of the Breast Cancer Navigator Role in Reducing Distress in Newly Diagnosed Breast Cancer Patients: A Pilot Study
The authors present their findings from a study testing the effects of an early intervention by the Breast Cancer Navigator on distress.
Danelle Johnston, MSN, RN, ONN-CG, OCN, of AONN+ Appointed to the Biden Cancer Initiative Advisory Committee
“Participating in a national conversation on improving cancer care is a great honor. We are being asked to reconsider how we address cancer from prevention through survivorship. It’s a huge undertaking, but a very exciting one. I’m delighted to be a part of it.” –Danelle Johnston, MSN, RN, ONN-CG, OCN
Federal health officials this week allowed a genetic testing firm to sell kits to consumers to test whether they carry gene mutations that put them at higher risk for breast and ovarian cancer.
JONS Editor in Chief, Lillie Shockney, RN, BS, MAS, ONN-CG, offers her insights on the timely topic of commercially available genetic testing.
Updated Colon and Rectal Cancer Guidelines Include Options for Surveillance and Shortened Duration of Adjuvant Treatment
The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.
The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
Results 1 - 9 of 9